ANXA1 and prostate carcinoma: Addressing these limitations through future research endeavours will improve the understanding of the role of RRM2, ANXA1, and the PI3K/AKT pathway in therapeutic resistance in prostate cancer and facilitate the development of more effective treatment strategies.